Bedel Financial Consulting’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bedel Financial Consulting’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-331	Closed	-$15K	–	240
2022 Q1	$15K	Hold	331	–	–	﹤0.01%	589
2021 Q4	$20K	Hold	331	–	–	0.01%	564
2021 Q3	$25K	Hold	331	–	–	0.01%	503
2021 Q2	$31K	Hold	331	–	–	0.01%	470
2021 Q1	$29K	Buy	331 +185	+127%	+$18.4K	0.01%	450
2020 Q4	$14K	Hold	146	–	–	0.01%	499
2020 Q3	$9K	Hold	146	–	–	﹤0.01%	527
2020 Q2	$8K	Hold	146	–	–	﹤0.01%	515
2020 Q1	$5K	Buy	+146	New	+$4.88K	﹤0.01%	563

Other funds holding ARKG

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Bedel Financial Consulting's ARKG Position: Q2 2022 in Review

Bedel Financial Consulting sold out of ARK Genomic Revolution ETF (ARKG) in Q2 2022, closing a stake of 331 shares — an estimated $15K sold.

Bedel Financial Consulting first reported a position in ARKG in Q1 2020 and held it in 9 quarters. The position peaked at $31K in Q2 2021. 333 funds tracked by Wall St. Rank hold ARKG as of Q2 2022.

Bedel Financial Consulting reported no remaining ARK Genomic Revolution ETF position as of Q2 2022 after selling out during the quarter.
Bedel Financial Consulting sold 331 ARK Genomic Revolution ETF shares in Q2 2022, an estimated $15K.
Bedel Financial Consulting first reported a position in ARK Genomic Revolution ETF in Q1 2020 and held it in 9 quarters.
Bedel Financial Consulting's ARK Genomic Revolution ETF position peaked at $31K in Q2 2021.
333 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.